This article discusses the recent FDA clearance given to 23andMe to report an additional 41 genetic variants associated with a higher risk of certain cancers. The company’s stock, ME, has risen nearly 16% in pre-market trading as a result of this news.
The newly approved variants are linked to an increased risk of breast, ovarian, prostate, and pancreatic cancers. They will be added to 23andMe’s Genetic Health Risk Report, providing customers with more comprehensive information.
In addition to the FDA clearance, 23andMe has also been granted a Predetermined Change Control Plan (PCCP). This allows the company to include more BRCA1 and BRCA2 variants and other cancer risk information in future reports without the need for premarket review.
In other news, United Parcel Service (UPS) is reportedly offering voluntary retirement packages to reduce the number of pilots on its payroll. The goal is for 167 pilots to accept the compensation package, which includes cash and healthcare benefits.
Finally, there have been discussions about potentially reclassifying cannabis as a Schedule III drug, which would make it less risky. However, Bernstein analysts suggest that this may not be the preferred outcome for cannabis producers and investors. Reclassification would still classify cannabis as a controlled substance, limiting its market potential.
Overall, these updates reflect significant developments in the fields of genetics, healthcare, and transportation.
For more information, please refer to the original article on Seeking Alpha.